Showing 5341-5350 of 7310 results for "".
- NRS Survey Finds Rosacea Patients Lack Knowledge of Antibiotic Resistancehttps://practicaldermatology.com/news/nrs-survey-finds-rosacea-patients-lack-knowledge-of-antibiotic-resistance/2460671/A majority of rosacea patients have never heard of antibiotic resistance, results of a recent survey by the National Rosacea Society (NRS) show. Yet topical or oral antibiotics are among the most commonly prescribed treatments for rosacea. The NRS’s rec
- Soliton, US Navy to Collaborate on Study of RAP for Fibrotic Scarshttps://practicaldermatology.com/news/soliton-us-navy-to-collaborate-on-study-of-rap-for-fibrotic-scars/2460670/Soliton, Inc. will collaborate with the US Navy to conduct a multi-treatment proof-of-concept clinical study to evaluate the safety and efficacy of multiple treatments with Soliton's Rapid Acoustic Pulse (RAP) device for the improvement in the appearance of fibrotic scars. The study
- Survey: Teledermatology Appointments Are Suitable Alternatives to Office Visitshttps://practicaldermatology.com/news/survey-teledermatology-appointments-are-suitable-alternatives-to-office-visits/2460669/The majority of dermatology patients find telehealth appointments to be a suitable alternative to in-person office visits, according to a survey in the Journal of Drugs in Dermatology.
- LEO Pharma Data: Tralokinumab Benefits Adult ADhttps://practicaldermatology.com/news/leo-pharma/2460662/Results from a post-hoc subanalysis of the Phase 3 ECZTRA 3 trial demonstrate the potential for LEO Pharma’s tralokinumab as a treatment for adults with moderate-to-severe atopic dermatitis. Investigational tralokinumab has not y
- Verrica: Post-Hoc Analyses Show Benefits of VP-102 at Specific Siteshttps://practicaldermatology.com/news/verrica-post-hoc-analyses-show-benefits-of-vp-102-at-specific-sites/2460661/Positive data from post-hoc pooled analyses of the pivotal Phase 3 CAMP trials demonstrate the safety and efficacy of Verrica Pharmaceuticals’ lead product candidate VP-102 in molluscum contagiosum (molluscum) in specific body regions. The data were presented in poster format online for the
- Cyspera Demonstrates Efficacy, Safety in Three Published Studieshttps://practicaldermatology.com/news/cyspera-demonstrates-efficacy-safety-in-three-published-studies/2460657/Several studies recently published in peer reviewed journals demonstrate the safety and efficacy of stabilized-cysteamine 5% cream (Cyspera), the novel, non-hydroquinone, topical pigment regulator from Scientis In a randomized, double-blinded study of 50 melasma patients assigned to eit
- Fitness Level Tied to Psoriasis Riskhttps://practicaldermatology.com/news/fitness-level-tied-to-psoriasis-risk/2460653/Low fitness levels may increase risk for psoriasis, according to a register-based study of military recruits. Specifically, male recruits to compulsory military training who were rated as the least fit had a 35 percent higher risk for psoriasis when compared to the f
- Cerave Poll: Healthier Skin Tops New Year’s Resolutionshttps://practicaldermatology.com/news/cerave-poll-healthier-skin-tops-new-years-resolution-lists/2460652/The COVID-19 pandemic has taken its toll on every aspect of life including skin, according to a new survey from CeraVe. Fully 62 percent of Americans agree that they have experienced more skin troubles during the pandemic than ever before, with top concerns being dryness (51
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Skyrizi Performs Well in Phase 3 Studies of PsAhttps://practicaldermatology.com/news/skyrizi-performs-well-in-phase-3-studies-of-psa/2460647/Two Phase 3 studies of Risankizumab (Skyrizi) show improvements in disease activity across joint and skin symptoms in patients with psoriatic arthritis. KEEPsAKE-1 and KEEPsAKE-2 found that significantly more patients treated with risankizumab (150 mg) achieved the primary end